2. Eton Pharmaceuticals Inc. (NASDAQ:ETON)
Price: $16.99 per share
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) has materially strengthened its rare disease growth profile following U.S. FDA approval of DESMODA™ (desmopressin acetate) Oral Solution, the first and only FDA-approved oral liquid formulation of desmopressin for the management of central diabetes insipidus, also known as arginine vasopressin deficiency. The approval represents a meaningful commercial inflection point for ETON stock, as DESMODA addresses a clear unmet need in a market of more than 13,000 U.S. patients, including thousands of pediatric cases where precise, individualized dosing is critical. By eliminating tablet splitting and crushing and delivering a ready-to-use 0.05 mg/mL oral solution, DESMODA introduces dosing flexibility and titration precision that clinicians have long sought in central diabetes insipidus treatment.
Commercial launch is expected March 9, with distribution through specialty pharmacy Anovo and support from the Eton Cares Program, which provides reimbursement assistance, patient education, and co-pay support, including potential $0 co-pay for qualifying patients. Management projects peak annual sales of $30–50 million, supported by patent protection extending through 2044, reinforcing long-term revenue visibility. Importantly, DESMODA will be promoted by Eton’s established pediatric endocrinology sales platform, which already markets ALKINDI SPRINKLE®, INCRELEX®, and KHINDIVITM, creating operational leverage and cross-selling opportunities within the rare endocrine community.
Central diabetes insipidus requires careful water balance management, as over- or under-dosing desmopressin can lead to serious complications, including hyponatremia and fluid imbalance. An FDA-approved oral liquid formulation designed for incremental dose adjustments directly addresses these clinical challenges and may become a foundational therapy in the category. For investors evaluating biotech stocks and rare disease pharmaceutical companies, Eton Pharmaceuticals now combines a growing portfolio of nine commercial products with multiple late-stage pipeline candidates, positioning ETON stock as a differentiated small-cap growth story in specialty pharma. With FDA validation, defined peak sales potential, and durable intellectual property, Eton’s latest approval strengthens the long-term bullish thesis centered on targeted rare disease commercialization and scalable revenue expansion.
Click next to see the following stock...
